Navigation Links
Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
Date:2/1/2010

PALO ALTO, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the 12th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 9 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases.  The company's most advanced investigational drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA®, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.

RELATED LINKS
http://www.telik.com

'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Second Quarter 2009 Financial Results
2. Telik Reports Preclinical Results at AACR Annual Meeting
3. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
4. Telik Announces New TRAP Drug Discovery Agreement
5. Telik Announces Financial Results for 2008 Third Quarter
6. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
7. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
8. Telik Announces Receipt of Nasdaq Notice
9. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
10. ReceptorBio Announces Diabetes License Agreement With Telik
11. Telik Announces Financial Results For 2008 Second Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- According to a report by Transparency Market Research ... to the presence of a large pool of participants; however, only ... and Sigma-Aldrich, compete with each other in this market. With Proliant ... 76% of this market in 2016.  ... As of now, a large number of vendors ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
Breaking Biology News(10 mins):